Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

NCT02129985 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether a combination of insulin and exenatide can help people with type 2 diabetes achieve better blood sugar control.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 25–70 · all sexes

Timeline Started 2014-02 · est. completion 2015-09

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02129985 ↗

Description as written by the study sponsor.

Whether GLP-1 receptor agonists sequential therapy in newly diagnosed type 2 diabetic patients can further improve glycemic control, diabetes remission rate and β-cell function after the short-term insulin intensive therapy.

Treatments tested

Exenatide also known as GLP-1 receptor agonist Drug

Exenatide (10 ug/bid for 3 months)
Metformin also known as Glucophage Drug

Metformin 850 mg/bid for 3 months

Main thing measured	time to glycaemic remission
Sponsor	xiaolong zhao
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02129985 ↗